Kenya set to receive injectable HIV preventive drug
Health & Science
By
Mercy Kahenda
| Jul 15, 2025
Kenya is set to receive Lenacapavir, a groundbreaking HIV preventive drug that will be administered as an injection just twice a year.
This makes it the first long-acting injectable form of pre-exposure prophylaxis (PrEP), offering an alternative to the daily oral pills currently used for HIV prevention.
"The Ministry of Health through the Division of National AIDS and STI Control Programme (NASCOP), in collaboration with various partners is working to ensure avaiability of the innovative product for Kenyans by January 2026," NASCOP has announced.
READ MORE
Why Kenya's zero-tariff deal with China is up in the air
Construction sector growth triples as road projects restart
Tea market sells 8.4 million kgs in the weekly auction
Kenyans face pain at the pump as Trump targets Venezuela oil
Economy shows signs of recovery in new boost for jobs and salaries
How the 52-Week challenge can support new year savings goals
Synergy between aviation and tourism can spur growth
Agricultural sector records lowest growth
Agency pushes for investment in agro-marine hubs, infrastructure
Over 80 per cent of city buildings unsafe due to graft, experts warn
Clinical data shows the drug has up to 99 percent efficacy in preventing HIV transmission.
“Lenacapavir is highly effective and long-lasting," added NASCOP.
The injection is administered under the skin in the abdominal area (stomach) by a healthcare provider and is designed to be discreet, convenient, and stigma-free.
Kenya is expected to receive the drug with procurement supported by the Global Fund and other partners.
The rollout will be coordinated by the Ministry of Health through NASCOP, in collaboration with partner organisations.
“This is a major milestone in our efforts to end HIV/AIDS by 2030,” NASCOP noted.
The official launch of Lenacapavir was announced following an agreement signed between the Global Fund and Gilead Sciences.
Alongside Kenya, other high HIV burden countries set to benefit from the new injectable PrEP include Botswana, Eswatini, Ethiopia, Lesotho, Malawi, Mozambique, Nigeria, South Africa, Tanzania, Uganda, Zambia, and Zimbabwe.